ATE420961T1 - Rekombinante anti-tumor rnase - Google Patents
Rekombinante anti-tumor rnaseInfo
- Publication number
- ATE420961T1 ATE420961T1 AT99914174T AT99914174T ATE420961T1 AT E420961 T1 ATE420961 T1 AT E420961T1 AT 99914174 T AT99914174 T AT 99914174T AT 99914174 T AT99914174 T AT 99914174T AT E420961 T1 ATE420961 T1 AT E420961T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- recombinant
- ribonucleases
- active
- rnase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7975198P | 1998-03-27 | 1998-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE420961T1 true ATE420961T1 (de) | 2009-01-15 |
Family
ID=22152577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99914174T ATE420961T1 (de) | 1998-03-27 | 1999-03-26 | Rekombinante anti-tumor rnase |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1068332B1 (de) |
AT (1) | ATE420961T1 (de) |
AU (1) | AU755147B2 (de) |
CA (1) | CA2324646A1 (de) |
DE (1) | DE69940307D1 (de) |
WO (1) | WO1999050398A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6869604B1 (en) | 1998-03-27 | 2005-03-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant anti-tumor RNAse |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3469247B2 (ja) * | 1996-02-21 | 2003-11-25 | アメリカ合衆国 | 組換えリボヌクレアーゼタンパク質 |
US6649392B1 (en) * | 1996-04-04 | 2003-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods |
DE69831224T2 (de) * | 1997-05-02 | 2006-03-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen |
-
1999
- 1999-03-26 DE DE69940307T patent/DE69940307D1/de not_active Expired - Fee Related
- 1999-03-26 CA CA002324646A patent/CA2324646A1/en not_active Abandoned
- 1999-03-26 AU AU32074/99A patent/AU755147B2/en not_active Ceased
- 1999-03-26 WO PCT/US1999/006641 patent/WO1999050398A2/en active IP Right Grant
- 1999-03-26 AT AT99914174T patent/ATE420961T1/de not_active IP Right Cessation
- 1999-03-26 EP EP99914174A patent/EP1068332B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU755147B2 (en) | 2002-12-05 |
EP1068332B1 (de) | 2009-01-14 |
WO1999050398A2 (en) | 1999-10-07 |
DE69940307D1 (de) | 2009-03-05 |
EP1068332A2 (de) | 2001-01-17 |
WO1999050398A3 (en) | 1999-12-23 |
CA2324646A1 (en) | 1999-10-07 |
AU3207499A (en) | 1999-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1200124A4 (de) | Immunglobulin fusionsproteine | |
ZA200200789B (en) | Multiple cytokine-antibody complexes. | |
WO1999002552A3 (en) | Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof | |
EP1553975B8 (de) | Optimierte fc-varianten und herstellungsverfahren dafür | |
NZ502392A (en) | Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals | |
WO2001016114A3 (en) | Heterocyclic compounds and methods for modulating cxcr3 function | |
EP1720996A4 (de) | Rekombinante zytotoxische rnasen enthaltende fusionsproteine | |
ATE229542T1 (de) | Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen | |
EP1501935A4 (de) | Kostengünstige herstellung von peptiden | |
NO20033673L (no) | Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur | |
DK1214344T3 (da) | Dipeptidylpeptidaser | |
WO2020247388A8 (en) | Il-2alpha receptor subunit binding compounds | |
WO2000048621A3 (en) | Methods and compositions for regulating protein-protein interactions | |
MXPA05003887A (es) | Antagonistas il - 15. | |
CR20230178A (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
IL125771A0 (en) | Recombinant ribonuclease proteins | |
WO2002070549A3 (en) | Chimeric polypeptides of serum albumin and uses related thereto | |
ATE420961T1 (de) | Rekombinante anti-tumor rnase | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
AU703179B2 (en) | Recombinant canine gastric lipase and pharmaceutical compositions | |
MXPA04002103A (es) | Una proteina de union a caspasa-8, su preparacion y uso. | |
WO2000068416A3 (de) | Methoden zur auffindung von proteasen, die spezifisch membrangebundene substrate spalten | |
GB2360772B (en) | Compounds for targeting | |
WO2002052022A3 (en) | Selective cytotoxic fusion proteins | |
WO2000042063A3 (de) | Peptide zur inhibierung von hbv-core-proteinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |